Apr 9
Proxy statement
DEF 14A
Proxy statement
ANIX · Anixa Biosciences Inc · Documents
Market Cap
$110.38M
Shares
34.76M
Volume · Nov 6
121.65K
Avg daily vol (3M)
277.39K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2021
Apr 2
Current report
8-K
Events of Mar 29
Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change
Mar 30
Proxy statement
PRE 14A
Proxy statement
Mar 24
Current report
8-K
Events of Mar 22
Entered into a material agreement
Mar 11
Quarterly report
10-Q
FY2021 Q1, ended Jan 31
Quarterly report for FY2021 Q1
Revenue $512.5K
Net loss $2.21M
Jan 28
Current report
8-K
Events of Jan 26
Entered into a material agreement
Jan 7
2020
Dec 1
Current report
8-K
Events of Nov 30
Entered into a material agreement
Sep 16
Current report
8-K
Regulation FD disclosure
Sep 8
Aug 17
Current report
8-K
Events of Aug 13
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
Jul 20
Proxy statement
DEFA14A
Proxy statement
Jul 2
Proxy statement
DEF 14A
Proxy statement
Jul 2
Current report
8-K
Other events
Jun 22
Proxy statement
PRE 14A
Proxy statement
Jun 9
Apr 20
Current report
8-K
Events of Apr 14
Entered into a material agreement
Mar 9
Jan 10
Annual report
10-K/A
Ended Oct 31
Annual report for the period ended Oct 31, 2019
Jan 9
Annual report
10-K
FY2019, ended Oct 31
Annual report for FY2019
Revenue $250K
▼ 77.5%
Net loss $11.82M
Showing 51–70 of 70 documents
Key facts
CIK
715446
CUSIP
03528H109
13F (30d)
25 filings
25 filers
Visit website
Investor relations